Orca-T and the Future of AlloHSCT: Addressing Unmet Needs

Summary for Physicians: Value of ORCA-T in AlloHSCT Treatment Landscape

ORCA-T adds significant value to the alloHSCT treatment landscape by addressing key unmet needs, as follows:

• Unmet need: It provides an effective, lower-toxicity option, particularly beneficial in reducing nonrelapse mortality and re-hospitalization rates, which are critical challenges in alloHSCT.
• Value added: ORCA-T offers improved clinical outcomes with reduced toxicity compared with traditional regimens.
• Impact on clinical perspectives: The reduction in nonrelapse mortality and rehospitalization rates enhances patient recovery and quality of life posttransplant.

Overall, ORCA-T represents a promising advance in alloHSCT, filling important gaps in current treatment strategies.

Nelli Bejanyan reports consulting or advisory role for CareDx, Medexus Pharmaceuticals, Orca Biosystems, AlloVir, TScan Therapeutics, and Pfizer; and research funding from CRISPR Therapeutics. Everett Meyer reports sponsored research from Orca Biosciences, Kyverna; and a scientific advisor role and equity holder for GigaMune, Indee, TRACT, Jura Biosciences.Caspian Oliai reports no relevant disclosures (investigator on the Orca T trial funded by Orca Biosciences). Arpita P. Gandhi reports roles with OncLive, MJH Life Sciences, OrcaBio (research), CareDx (Advisory Board). Amandeep Salhotra reports received funding from Rigel, Bristol Myers Squibb and Orca Biosciences; and speakers bureau for Incyte and Sanofi.